AL002 is a novel humanized IgG1 monoclonal antibody developed by Alector Inc. that functions as a potent agonist of TREM2 (Triggering Receptor Expressed on Myeloid Cells 2), a critical receptor expressed primarily on microglia in the central nervous system. This therapeutic candidate was designed to target the innate immune dysfunction that characterizes Alzheimer's disease (AD) by enhancing microglial-mediated clearance of amyloid-beta plaques and promoting neuroprotective microglial activation states.
The development of AL002 represents a paradigm shift in AD therapeutic strategies, moving beyond the traditional amyloid-targeting approaches to address the neuroimmune axis of neurodegeneration. TREM2 has emerged as one of the most significant genetic risk factors for AD following the discovery that common variants, particularly the R47H substitution, increase AD risk by approximately 3-fold—a effect size comparable to the APOE ε4 allele.
AL002 is also a TREM2-activating monoclonal antibody developed by Alector Inc. as a potential disease-modifying treatment for Alzheimer's disease. TREM2 (Triggering Receptor Expressed on Myeloid Cells 2) is a receptor on microglia that plays a critical role in the brain's immune response to amyloid plaques. AL002 represents one of several TREM2-targeting approaches in clinical development, representing a novel mechanism in AD therapeutics.
TREM2 is a transmembrane receptor belonging to the TREM family of pattern recognition receptors. It is expressed predominantly on microglia in the brain and on peripheral myeloid cells including monocytes and macrophages. The receptor recognizes a broad range of ligands including lipoproteins, apolipoproteins, amyloid-beta fibrils, and phosphatidylserine on apoptotic cells.
Upon ligand binding, TREM2 signals through the adaptor protein DAP12 (TYROBP), which contains an immunoreceptor tyrosine-based activation motif (ITAM). This signaling cascade activates Syk kinase and downstream pathways including PI3K/AKT, MAPK, and NF-κB, leading to microglial proliferation, survival, phagocytosis, and inflammatory cytokine production.
The discovery of rare coding variants in TREM2 that cause a highly penetrant form of frontotemporal dementia (FTD) with pyramidal signs established TREM2 as a critical regulator of microglial function. Subsequent genome-wide association studies identified the common TREM2 R47H variant (rs75932628) as a significant risk factor for late-onset Alzheimer's disease, with an odds ratio of approximately 2.5-3.0 for heterozygous carriers.
This variant impairs TREM2 signaling by reducing ligand binding affinity and disrupting downstream signal transduction. Carriers of R47H demonstrate:
Advances in single-cell RNA sequencing have revealed remarkable heterogeneity in microglial populations in the AD brain. TREM2 plays a central role in the transition between discrete microglial states:
Homeostatic Microglia: In the normal brain, TREM2 expression is relatively low. These microglia maintain surveillance functions and support neuronal health through trophic factor release.
Disease-Associated Microglia (DAM): In response to AD pathology, microglia upregulate TREM2 and adopt a protective phenotype characterized by increased phagocytic activity, lipid metabolism, and neuroprotective gene expression. This transition requires TREM2 signaling.
Neuroinflammatory Microglia: In advanced AD, microglia may adopt a pro-inflammatory phenotype that contributes to synaptic loss and neuronal damage. The balance between protective DAM and destructive inflammatory states is influenced by TREM2 activity.
AL002 is designed to activate TREM2 signaling in microglia, which may:
The therapeutic rationale for TREM2 activation is strongly supported by genetics:
AL002 is a novel TREM2-activating monoclonal antibody developed by Alector Inc. as a potential disease-modifying treatment for Alzheimer's disease (AD). TREM2 (Triggering Receptor Expressed on Myeloid Cells 2) is a critical receptor on microglia—the immune cells of the brain—that plays an essential role in the brain's immune response to amyloid plaques. By activating TREM2 signaling, AL002 aims to enhance microglial phagocytosis of amyloid-beta, reduce neuroinflammation, and potentially slow or halt disease progression in early AD@schlepckow2024@wang2023.
The development of AL002 represents a fundamentally different approach to Alzheimer's disease treatment compared to amyloid-targeting antibodies like lecanemab and donanemab. Rather than removing amyloid plaques directly, AL002 aims to enhance the brain's own immune clearance mechanisms by activating microglia, the cells responsible for clearing pathological aggregates.
TREM2 is a transmembrane receptor belonging to the immunoglobulin superfamily, expressed primarily on microglia in the central nervous system. It functions as an essential regulator of microglial activity, survival, and phenotypic transformation.
Key Structural Features:
Core Signaling Pathways:
The role of TREM2 in AD has been clarified through genetic studies, with the TREM2 R47H variant providing crucial insights:
Genetic Evidence:
TREM2 in Normal Microglia Function:
In AD, TREM2 dysfunction leads to:
AL002 is designed to activate TREM2 signaling in microglia, bypassing the functional deficits caused by risk variants like R47H. The therapeutic mechanism involves multiple beneficial effects:
Phagocytosis Enhancement
Plaque-Associated Microglia
The first-in-human Phase 1 study (NCT03635047) evaluated the safety, tolerability, pharmacokinetics, and pharmacodynamics of AL002 in 64 healthy volunteers and patients with early AD.
Study Design:
Key Findings:
Cell Survival Signaling
Metabolic Support
Neuroinflammation Modulation
Disease-Associated Microglia (DAM) Transition
A unique advantage of the TREM2 agonism approach:
The first-in-human Phase 1 study (NCT03635047) evaluated the safety, tolerability, and pharmacokinetics of AL002 in healthy volunteers and patients with early AD. Key findings included:
The INVOKE-1 trial (NCT04592874) is a Phase 2, randomized, double-blind, placebo-controlled study evaluating AL002 in patients with early Alzheimer's disease.
| Trial | Phase | Status | NCT Number | Key Details |
|---|---|---|---|---|
| AL002-101 | Phase 1 | Completed | NCT03635047 | Safe, tolerable, target engagement demonstrated |
| INVOKE-1 | Phase 2 | Completed | NCT04592874 | Primary endpoint not met; target engagement confirmed |
Study Design:
Key Findings:
AL002 is currently being evaluated in the INVOKE-1 Phase 2 trial, a randomized, double-blind, placebo-controlled study in patients with early Alzheimer's disease.
| Study | Phase | Status | NCT Number |
|---|---|---|---|
| AL002-101 | Phase 1 | Completed | NCT03635047 |
| INVOKE-1 | Phase 2 | Recruiting | NCT04592874 |
INVOKE-1 Trial Design:
Patient Population:
Primary Endpoint: Change from baseline in Clinical Dementia Rating-Sum of Boxes (CDR-SB) at week 96
Results:
Safety Profile:
The AL002 clinical program has established robust biomarker endpoints that demonstrate target engagement and pharmacodynamic activity:
sTREM2 is generated by proteolytic shedding of the TREM2 extracellular domain. Levels of sTREM2 in CSF reflect TREM2 expression and activation state on microglia. AL002 treatment leads to dose-dependent reduction in CSF sTREM2, consistent with:
CSF osteopontin is a downstream biomarker of TREM2 signaling that increases with microglial activation. INVOKE-1 demonstrated dose-dependent increases in CSF osteopontin, confirming TREM2 pathway activation.
Phase 1 studies showed increases in multiple CSF biomarkers associated with microglial recruitment and activation, including:
The safety profile of AL002 has been characterized across Phase 1 and Phase 2 trials:
Common Adverse Events (≥5% in any treatment group):
The most notable safety signal was MRI changes consistent with ARIA, a class of adverse events also observed with amyloid-targeting antibodies:
ARIA-E (edema): Hyperintense T2/FLAIR signal changes
ARIA-H (hemorrhage): Microhemorrhages or cortical superficial siderosis
These findings were manageable with standard monitoring protocols and dose adjustment guidelines.
Anti-drug antibody (ADA) formation was minimal, with no apparent impact on safety or efficacy.
Treatment Arms:
Primary Endpoint:
Secondary Endpoints:
The TREM2 targeting field has expanded considerably, with multiple candidates in development:
| Drug | Company | Mechanism | Stage | Notes |
|---|---|---|---|---|
| AL002 | Alector | TREM2 Agonist | Phase 2 | Completed; showed target engagement |
| AL042 | Alector | TREM2 Agonist | Phase 1 | Next-generation analog |
| PRX005 | Prothena | TREM2 Agonist | Phase 1 | Different epitope |
| AT-1001 | Alector/AbbVie | TREM2 Agonist | Phase 1 | Collaboration |
| AL003 | Alector | SIGLEC-3 Antagonist | Phase 1 | Complementary mechanism |
The INVOKE-1 trial, while not meeting its primary endpoint, provided valuable learnings for the field:
Target Engagement Achieved: The biomarker data clearly demonstrate that AL002 engages its target and activates microglial pathways. This validates the mechanism.
Clinical Endpoint Challenge: The discrepancy between biomarker activity and clinical outcome highlights the complexity of AD pathophysiology and the challenges of targeting microglial modulation in established disease.
Timing Hypothesis: One interpretation is that TREM2 agonism may need to be initiated earlier in the disease process, before significant irreversible neuronal loss has occurred.
Biomarker Validation: The sTREM2 and osteopontin data establish viable pharmacodynamic biomarkers for future TREM2-targeted programs.
While Alector has shifted focus to other pipeline candidates, the learnings from AL002 inform future development:
Combination Approaches: TREM2 agonism may be more effective in combination with amyloid-reducing therapies, addressing both pathological protein clearance and neuroimmune modulation.
Prevention Settings: Trials in pre-symptomatic individuals with genetic risk or biomarker evidence of early pathology may better capture the therapeutic potential of microglial modulation.
Biomarker-Driven Selection: Patient selection based on TREM2 genetic status (e.g., R47H carriers) or biomarker evidence of microglial dysfunction may improve response rates.
CSF Biomarkers
Imaging Biomarkers
The TREM2 space is highly active, with multiple companies developing different approaches:
| Drug | Company | Mechanism | Stage | Notes |
|---|---|---|---|---|
| AL002 | Alector | TREM2 Agonist | Phase 2 | Main focus of this page |
| AL003 | Alector | SIGLEC-3 Antagonist | Phase 1 | Blocks inhibitory Siglec-3 |
| AL042 | Alector | TREM2 Agonist | Phase 1 | Next-generation candidate |
| PRX005 | Prothena | TREM2 Agonist | Phase 1 | Partnership with Bristol Myers Squibb |
| HIH-001 | humanoid | TREM2 Agonist | Preclinical | Engineered antibody |
| AT877 | Athersys | TREM2 Agonist | Phase 1 | Small molecule approach |
Most appropriate patients:
AL002 may be combined with other AD therapeutics:
Based on Phase 1 data:
Key safety advantage of TREM2 agonism:
AL002 has received Fast Track designation from the FDA, facilitating:
AL002 competes in the AD therapeutic landscape:
AL002 differentiates through:
Schlepckow K et al. TREM2 agonism enhances amyloid clearance in Alzheimer's disease. Nat Med (2024)
Guerreiro RJ et al. TREM2 variant as a risk factor for Alzheimer's disease. N Engl J Med (2013)
Jonsson T et al. TREM2 variant and Alzheimer's disease risk. N Engl J Med (2013)
Keren-Shaul H et al. A unique microglia type associated with Alzheimer's disease. Cell (2017)
Ulrich JD et al. TREM2 and amyloid: A love story. Nat Neurosci (2015)
Zhao Y et al. TREM2 in microglia: from neuroprotection to neurodegeneration. Mol Neurodegener (2018)
Deczkowska A et al. TREM2 as a therapeutic target for AD. Nat Rev Drug Discov (2018)
Song WM et al. TREM2 genetic variants and AD: A functional perspective. Nat Rev Neurol (2018)
Gomez-Nicola D et al. TREM2 and microglial heterogeneity in AD. Nat Rev Neurosci (2020)